2019 Vol. 10(3)

Recollection
Si-Ho Tchou: life of a legend from physiology to psychology
Wei Chen, Xi Chen, Shengjun Wen
2019, 10(3): 157-160. doi: 10.1007/s13238-018-0553-4
Abstract:
Research articles
Chemical genomics reveals inhibition of breast cancer lung metastasis by Ponatinib via c-Jun
Wei Shao, Shasha Li, Lu Li, Kequan Lin, Xinhong Liu, Haiyan Wang, Huili Wang, Dong Wang
2019, 10(3): 161-177. doi: 10.1007/s13238-018-0533-8
Abstract:
Metastasis is the leading cause of human cancer deaths. Unfortunately, no approved drugs are available for antimetastatic treatment. In our study, high-throughput sequencing-based high-throughput screening (HTS2) and a breast cancer lung metastasis (BCLM)-associated gene signature were combined to discover anti-metastatic drugs. After screening of thousands of compounds, we identified Ponatinib as a BCLM inhibitor. Ponatinib significantly inhibited the migration and mammosphere formation of breast cancer cells in vitro and blocked BCLM in multiple mouse models. Mechanistically, Ponatinib represses the expression of BCLM-associated genes mainly through the ERK/c-Jun signaling pathway by inhibiting the transcription of JUN and accelerating the degradation of c-Jun protein. Notably, JUN expression levels were positively correlated with BCLM-associated gene expression and lung metastases in breast cancer patients. Collectively, we established a novel approach for the discovery of anti-metastatic drugs, identified Ponatinib as a new drug to inhibit BCLM and revealed c-Jun as a crucial factor and potential drug target for BCLM. Our study may facilitate the therapeutic treatment of BCLM as well as other metastases.
Identification of serotonin 2A receptor as a novel HCV entry factor by a chemical biology strategy
Lin Cao, Jizheng Chen, Yaxin Wang, Yuting Yang, Jie Qing, Zihe Rao, Xinwen Chen, Zhiyong Lou
2019, 10(3): 178-195. doi: 10.1007/s13238-018-0521-z
Abstract:
Hepatitis C virus (HCV) is a leading cause of liver disease worldwide. Although several HCV protease/polymerase inhibitors were recently approved by U.S. FDA, the combination of antivirals targeting multiple processes of HCV lifecycle would optimize anti-HCV therapy and against potential drug-resistance. Viral entry is an essential target step for antiviral development, but FDA-approved HCV entry inhibitor remains exclusive. Here we identify serotonin 2A receptor (5-HT2AR) is a HCV entry factor amendable to therapeutic intervention by a chemical biology strategy. The silencing of 5-HT2AR and clinically available 5-HT2AR antagonist suppress cell culture-derived HCV (HCVcc) in different liver cells and primary human hepatocytes at late endocytosis process. The mechanism is related to regulate the correct plasma membrane localization of claudin 1 (CLDN1). Moreover, phenoxybenzamine (PBZ), an FDAapproved 5-HT2AR antagonist, inhibits all major HCV genotypes in vitro and displays synergy in combination with clinical used anti-HCV drugs. The impact of PBZ on HCV genotype 2a is documented in immune-competent humanized transgenic mice. Our results not only expand the understanding of HCV entry, but also present a promising target for the invention of HCV entry inhibitor.
Myeloid-specific targeting of Notch ameliorates murine renal fibrosis via reduced infiltration and activation of bone marrowderived macrophage
Yali Jiang, Yuanyuan Wang, Pengfei Ma, Dongjie An, Junlong Zhao, Shiqian Liang, Yuchen Ye, Yingying Lu, Peng Zhang, Xiaowei Liu, Hua Han, Hongyan Qin
2019, 10(3): 196-210. doi: 10.1007/s13238-018-0527-6
Abstract:
Macrophages play critical roles in renal fibrosis. However, macrophages exhibit ontogenic and functional heterogeneities, and which population of macrophages contributes to renal fibrosis and the underlying mechanisms remain unclear. In this study, we genetically targeted Notch signaling by disrupting the transcription factor recombination signal binding protein-Jκ (RBP-J), to reveal its role in regulation of macrophages during the unilateral ureteral obstruction (UUO)-induced murine renal fibrosis. Myeloid-specific disruption of RBP-J attenuated renal fibrosis with reduced extracellular matrix deposition and myofibroblast activation, as well as attenuated epithelial-mesenchymal transition, likely owing to the reduced expression of TGF-β. Meanwhile, RBP-J deletion significantly hampered macrophage infiltration and activation in fibrotic kidney, although their proliferation appeared unaltered. By using macrophage clearance experiment, we found that kidney resident macrophages made negligible contribution, but bone marrow (BM)-derived macrophages played a major role in renal fibrogenesis. Further mechanistic analyses showed that Notch blockade reduced monocyte emigration from BM by down-regulating CCR2 expression. Finally, we found that myeloid-specific Notch activation aggravated renal fibrosis, which was mediated by CCR2+ macrophages infiltration. In summary, our data have unveiled that myeloid-specific targeting of Notch could ameliorate renal fibrosis by regulating BM-derived macrophages recruitment and activation, providing a novel strategy for intervention of this disease.
Letters
Channel activity of mirror-image M2 proton channel of influenza A virus is blocked by achiral or chiral inhibitors
Qing-Yan Guo, Long-Hua Zhang, Chao Zuo, Dong-Liang Huang, Zhipeng A. Wang, Ji-Shen Zheng, Chang-Lin Tian
2019, 10(3): 211-216. doi: 10.1007/s13238-018-0536-5
Abstract:
Engineering vascularized skeletal muscle tissue with transcriptional factor ETV2-induced autologous endothelial cells
Guanrong Yan, Ruibin Yan, Cheng Chen, Yanqiu Zhao, Wei Qin, Matthew B. Veldman, Song Li, Shuo Lin
2019, 10(3): 217-222. doi: 10.1007/s13238-018-0542-7
Abstract:
5' capped and 3' polyA-tailed sgRNAs enhance the efficiency of CRISPR-Cas9 system
Wei Mu, Yongping Zhang, Xutong Xue, Lei Liu, Xiaofei Wei, Haoyi Wang
2019, 10(3): 223-228. doi: 10.1007/s13238-018-0552-5
Abstract:
Terminal transfer amplification and sequencing for high-efficiency and lowbias copy number profiling of fragmented DNA samples
Dongqing Jiang, Xiannian Zhang, Yuhong Pang, Jianyun Zhang, Jianbin Wang, Yanyi Huang
2019, 10(3): 229-233. doi: 10.1007/s13238-018-0540-9
Abstract:

Current Issue

March, 2019

Volume 10, Issue 3

Pages 157-233

About the cover

Metastasis is the leading cause of human cancer deaths.Unfortunately, no approved drugs are available for antimetastatic treatment. In this study, high-throughputsequencing-based high-throughput screening (HTS2) anda breast cancer lung metastasis (BCLM)-associated genesignature were combined to discover anti-metastatic drugs.After screening of thousands of compounds, Shao et al.identifed Ponatinib as a BCLM inhibitor. Ponatinib signifcantlyinhibited the migration and mammosphere formation of breastcancer cells in vitro and blocked BCLM in multiple mousemodels. This study may facilitate the therapeutic treatment ofBCLM as well as other metastases.

Institute of Biophysics, Chinese Academy of Sciences, 15 Datun Road, Chaoyang Beijing 100101, China

Tel: (86-10) 64888620   Fax: (86-10) 64880586   E-mail: protein_cell@biols.ac.cn